The cumulative incidence of HCC development for the group with AFP level < 5.6 ng/mL at the end of DAA therapy was significantly lower than that for the group with AFP level ≥ 5.6 ng/mL (log-rank test p < 0.001). This evidence concerns the gene AFP and hepatocellular carcinoma.